BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Get away from the Tedious Drudgery: Go into Business Today! - 2Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- 3The Development of Shipping: Controlling Towards a More Associated Future
- 4Figure out What Shift Differentials Mean for Your General Attendant Compensation
- 5Fascinating Fishing Objections From Around The World
- ONE returns to Red Sea with new service
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Top 10 Moving Style Architects of the Year
- Vote In favor of Your Favored Pizza Cover
- 6 Hints to Upgrade Your Appeal, In addition to Your Outlook
- 10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide
- The race is on to turn your body into a GLP-1 factory
- In blow to Lula, Brazil Congress revives controversial environmental bill
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
